Ibex Investors’s Array Biopharma Inc ARRY Stock Holding History

Ibex Investors’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,784	Closed	-$307K	–	273
2018 Q1	$307K	Buy	+18,784	New	+$301K	0.25%	74

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ibex Investors's ARRY Position: Q2 2018 in Review

Ibex Investors sold out of Array Biopharma Inc (ARRY) in Q2 2018, closing a stake of 18,784 shares — an estimated $307K sold.

Ibex Investors first reported a position in ARRY in Q1 2018 and held it in 1 quarter. The position peaked at $307K in Q1 2018. 223 funds tracked by Wall St. Rank hold ARRY as of Q2 2018.

Ibex Investors reported no remaining Array Biopharma Inc position as of Q2 2018 after selling out during the quarter.
Ibex Investors sold 18,784 Array Biopharma Inc shares in Q2 2018, an estimated $307K.
Ibex Investors first reported a position in Array Biopharma Inc in Q1 2018 and held it in 1 quarter.
Ibex Investors's Array Biopharma Inc position peaked at $307K in Q1 2018.
223 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2018.

Based on Ibex Investors's 13F filing for Q2 2018, filed 14 Aug 2018.